(BYSI) –
-
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
-
Form 6-K BeyondSpring Inc. For: Mar 18
-
BeyondSpring (BYSI) Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
-
Form 6-K BeyondSpring Inc. For: Feb 26
-
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
-
Form SC 13G/A BeyondSpring Inc. Filed by: Ever Regal Group Ltd
-
Form 6-K BeyondSpring Inc. For: Jun 30
-
Form 6-K BeyondSpring Inc. For: Jan 16
-
BeyondSpring (BYSI) Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
-
Form 6-K BeyondSpring Inc. For: Jan 10
-
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
-
Form 6-K BeyondSpring Inc. For: Dec 18
-
BeyondSpring (BYSI) Receives Nasdaq Non-compliance Notice
-
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
-
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumor
-
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient De
-
Form 6-K BeyondSpring Inc. For: Oct 30
-
BeyondSpring (BYSI) Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
-
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
-
Form 6-K BeyondSpring Inc. For: Oct 04
-
BeyondSpring (BYSI) Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
-
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
-
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
-
Form 6-K BeyondSpring Inc. For: Sep 20
-
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
-
Form 6-K BeyondSpring Inc. For: Jul 14
-
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
-
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
-
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
-
Form 6-K BeyondSpring Inc. For: May 12
-
BeyondSpring Inc. (BYSI) PT Lowered to $1.25 at Baird
-
Form 6-K BeyondSpring Inc. For: Apr 18
-
Form 20-F BeyondSpring Inc. For: Dec 31
-
BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
-
BeyondSpring Files 2022 Annual Report on Form 20-F
-
Form SC 13G/A BeyondSpring Inc. Filed by: Ever Regal Group Ltd
-
BeyondSpring Inc. (BYSI) PT Lowered to $4 at Baird
-
Form 6-K BeyondSpring Inc. For: Mar 14
-
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
-
Form 6-K BeyondSpring Inc. For: Jun 30
-
Form 6-K BeyondSpring Inc. For: Feb 24
-
Form SC 13G/A BeyondSpring Inc. Filed by: Ever Regal Group Ltd
-
BeyondSpring (BYSI) Receives Notifications from Nasdaq Regarding Compliance With Listing Rules
-
Form 6-K BeyondSpring Inc. For: Jan 09
-
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules
-
BeyondSpring Inc. (BYSI) PT Lowered to $1 at BofA Securities
-
Form 6-K BeyondSpring Inc. For: Dec 30
-
BeyondSpring (BYSI) Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conference
Back to BYSI Stock Lookup
